<?xml version='1.0' encoding='utf-8'?>
<document id="25913040"><sentence text="No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study."><entity charOffset="48-60" id="DDI-PubMed.25913040.s1.e0" text="pantoprazole" /><entity charOffset="65-78" id="DDI-PubMed.25913040.s1.e1" text="mycophenolate" /><pair ddi="false" e1="DDI-PubMed.25913040.s1.e0" e2="DDI-PubMed.25913040.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25913040.s1.e0" e2="DDI-PubMed.25913040.s1.e1" /></sentence><sentence text="Mycophenolic acid (MPA) suppresses lymphocyte proliferation through inosine monophosphate dehydrogenase (IMPDH) inhibition"><entity charOffset="0-17" id="DDI-PubMed.25913040.s2.e0" text="Mycophenolic acid" /><entity charOffset="19-22" id="DDI-PubMed.25913040.s2.e1" text="MPA" /><entity charOffset="68-89" id="DDI-PubMed.25913040.s2.e2" text="inosine monophosphate" /><pair ddi="false" e1="DDI-PubMed.25913040.s2.e0" e2="DDI-PubMed.25913040.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25913040.s2.e0" e2="DDI-PubMed.25913040.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25913040.s2.e0" e2="DDI-PubMed.25913040.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s2.e1" e2="DDI-PubMed.25913040.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25913040.s2.e1" e2="DDI-PubMed.25913040.s2.e2" /></sentence><sentence text=" Two formulations have been approved: mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS)"><entity charOffset="38-59" id="DDI-PubMed.25913040.s3.e0" text="mycophenolate mofetil" /><entity charOffset="61-64" id="DDI-PubMed.25913040.s3.e1" text="MMF" /><entity charOffset="85-105" id="DDI-PubMed.25913040.s3.e2" text="mycophenolate sodium" /><entity charOffset="107-113" id="DDI-PubMed.25913040.s3.e3" text="EC-MPS" /><pair ddi="false" e1="DDI-PubMed.25913040.s3.e0" e2="DDI-PubMed.25913040.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25913040.s3.e0" e2="DDI-PubMed.25913040.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25913040.s3.e0" e2="DDI-PubMed.25913040.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s3.e0" e2="DDI-PubMed.25913040.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25913040.s3.e1" e2="DDI-PubMed.25913040.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25913040.s3.e1" e2="DDI-PubMed.25913040.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s3.e1" e2="DDI-PubMed.25913040.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25913040.s3.e2" e2="DDI-PubMed.25913040.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s3.e2" e2="DDI-PubMed.25913040.s3.e3" /></sentence><sentence text=" Pantoprazole (PAN) inhibits gastric acid secretion, which may alter MPA exposure"><entity charOffset="1-13" id="DDI-PubMed.25913040.s4.e0" text="Pantoprazole" /><entity charOffset="15-18" id="DDI-PubMed.25913040.s4.e1" text="PAN" /><entity charOffset="69-71" id="DDI-PubMed.25913040.s4.e2" text="MPA" /><pair ddi="false" e1="DDI-PubMed.25913040.s4.e0" e2="DDI-PubMed.25913040.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25913040.s4.e0" e2="DDI-PubMed.25913040.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25913040.s4.e0" e2="DDI-PubMed.25913040.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s4.e1" e2="DDI-PubMed.25913040.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25913040.s4.e1" e2="DDI-PubMed.25913040.s4.e2" /></sentence><sentence text=" Data from healthy volunteers suggest a significant drug-drug interaction (DDA) between pantoprazole and MPA"><entity charOffset="88-100" id="DDI-PubMed.25913040.s5.e0" text="pantoprazole" /><entity charOffset="105-108" id="DDI-PubMed.25913040.s5.e1" text="MPA" /><pair ddi="false" e1="DDI-PubMed.25913040.s5.e0" e2="DDI-PubMed.25913040.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25913040.s5.e0" e2="DDI-PubMed.25913040.s5.e1" /></sentence><sentence text=" In transplant patients, a decreased MPA area under the concentration-time curve (AUC) may lead to higher IMPDH activity, which may lead to higher acute rejection risk"><entity charOffset="37-39" id="DDI-PubMed.25913040.s6.e0" text="MPA" /></sentence><sentence text=" Therefore this DDA was evaluated in renal transplant patients under maintenance immunosuppressive therapy" /><sentence text="" /><sentence text="In this single-centre, open, randomized, four-sequence, four-treatment crossover study, the influence of PAN 40 mg on MPA pharmacokinetics such as (dose-adjusted) AUC0-12 h (dAUC) was analysed in 20 renal transplant patients (&gt;6 months post-transplantation) receiving MMF (1-2 g day(-1) ) and EC-MPS in combination with ciclosporin"><entity charOffset="320-331" id="DDI-PubMed.25913040.s9.e0" text="ciclosporin" /><entity charOffset="118-128" id="DDI-PubMed.25913040.s9.e1" text="MPA" /><entity charOffset="268-278" id="DDI-PubMed.25913040.s9.e2" text="MMF" /><entity charOffset="105-115" id="DDI-PubMed.25913040.s9.e3" text="PAN" /><pair ddi="false" e1="DDI-PubMed.25913040.s9.e3" e2="DDI-PubMed.25913040.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25913040.s9.e3" e2="DDI-PubMed.25913040.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25913040.s9.e3" e2="DDI-PubMed.25913040.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s9.e3" e2="DDI-PubMed.25913040.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25913040.s9.e1" e2="DDI-PubMed.25913040.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25913040.s9.e1" e2="DDI-PubMed.25913040.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s9.e1" e2="DDI-PubMed.25913040.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25913040.s9.e2" e2="DDI-PubMed.25913040.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s9.e2" e2="DDI-PubMed.25913040.s9.e0" /></sentence><sentence text=" The major metabolite MPA glucuronide (MPAG) and the IMPDH activity were also examined"><entity charOffset="26-37" id="DDI-PubMed.25913040.s10.e0" text="glucuronide" /><entity charOffset="39-43" id="DDI-PubMed.25913040.s10.e1" text="MPAG" /><entity charOffset="22-25" id="DDI-PubMed.25913040.s10.e2" text="MPA" /><pair ddi="false" e1="DDI-PubMed.25913040.s10.e2" e2="DDI-PubMed.25913040.s10.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s10.e2" e2="DDI-PubMed.25913040.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25913040.s10.e2" e2="DDI-PubMed.25913040.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25913040.s10.e0" e2="DDI-PubMed.25913040.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25913040.s10.e0" e2="DDI-PubMed.25913040.s10.e1" /></sentence><sentence text="" /><sentence text="MMF + PAN intake led to a lowest mean dAUC for MPA of 41"><entity charOffset="47-49" id="DDI-PubMed.25913040.s12.e0" text="MPA" /><entity charOffset="0-2" id="DDI-PubMed.25913040.s12.e1" text="MMF" /><entity charOffset="6-8" id="DDI-PubMed.25913040.s12.e2" text="PAN" /><pair ddi="false" e1="DDI-PubMed.25913040.s12.e1" e2="DDI-PubMed.25913040.s12.e1" /><pair ddi="false" e1="DDI-PubMed.25913040.s12.e1" e2="DDI-PubMed.25913040.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s12.e1" e2="DDI-PubMed.25913040.s12.e0" /><pair ddi="false" e1="DDI-PubMed.25913040.s12.e2" e2="DDI-PubMed.25913040.s12.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s12.e2" e2="DDI-PubMed.25913040.s12.e0" /></sentence><sentence text="46 ng h ml(-1) mg(-1) [95% confidence interval (CI) 32" /><sentence text="38, 50" /><sentence text="54], while MPA exposure was highest for EC-MPS + PAN [dAUC: 46"><entity charOffset="11-13" id="DDI-PubMed.25913040.s15.e0" text="MPA" /><entity charOffset="49-51" id="DDI-PubMed.25913040.s15.e1" text="PAN" /><pair ddi="false" e1="DDI-PubMed.25913040.s15.e0" e2="DDI-PubMed.25913040.s15.e0" /><pair ddi="false" e1="DDI-PubMed.25913040.s15.e0" e2="DDI-PubMed.25913040.s15.e1" /></sentence><sentence text="30 ng h ml(-1) mg(-1) (95% CI 37" /><sentence text="11, 55" /><sentence text="49)]" /><sentence text=" Differences in dAUC and dose-adjusted maximum concentration (dCmax) were not significant" /><sentence text=" Only for MMF [dAUC: 41"><entity charOffset="10-12" id="DDI-PubMed.25913040.s20.e0" text="MMF" /></sentence><sentence text="46 ng h ml(-1) mg(-1) (95% CI 32" /><sentence text="38, 50" /><sentence text="54)] and EC-MPS [dAUC: 43" /><sentence text="39 ng h ml(-1) mg(-1) (95% CI 33" /><sentence text="44, 53" /><sentence text="34)] bioequivalence was established for dAUC [geometric mean ratio: 101" /><sentence text="25% (90% CI 84" /><sentence text="60, 121" /><sentence text="17)]" /><sentence text=" Simultaneous EC-MPS + PAN intake led to an earlier time to Cmax (tmax) [median: 2"><entity charOffset="23-25" id="DDI-PubMed.25913040.s30.e0" text="PAN" /></sentence><sentence text="0 h (min-max: 0" /><sentence text="5-10" /><sentence text="0)] than EC-MPS intake alone [3 h (1" /><sentence text="5-12" /><sentence text="0); P = 0" /><sentence text="037]" /><sentence text=" Tmax was not affected for MMF [1"><entity charOffset="27-29" id="DDI-PubMed.25913040.s37.e0" text="MMF" /></sentence><sentence text="0 h (0" /><sentence text="5-5" /><sentence text="0)] ± pantoprazole [1"><entity charOffset="0-18" id="DDI-PubMed.25913040.s40.e0" text="0)] ± pantoprazole" /></sentence><sentence text="0 h (0" /><sentence text="5-6" /><sentence text="0), P = 0" /><sentence text="928)" /><sentence text=" No impact on MPAG pharmacokinetics or IMPDH activity was found"><entity charOffset="14-31" id="DDI-PubMed.25913040.s45.e0" text="MPA" /></sentence><sentence text="" /><sentence text="Pantoprazole influences EC-MPS and MMF pharmacokinetics but as it had no impact on MPA pharmacodynamics, the immunosuppressive effect of the drug was not impaired"><entity charOffset="0-12" id="DDI-PubMed.25913040.s47.e0" text="Pantoprazole" /><entity charOffset="83-94" id="DDI-PubMed.25913040.s47.e1" text="MPA" /><entity charOffset="35-46" id="DDI-PubMed.25913040.s47.e2" text="MMF" /><pair ddi="false" e1="DDI-PubMed.25913040.s47.e0" e2="DDI-PubMed.25913040.s47.e0" /><pair ddi="false" e1="DDI-PubMed.25913040.s47.e0" e2="DDI-PubMed.25913040.s47.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s47.e0" e2="DDI-PubMed.25913040.s47.e1" /><pair ddi="false" e1="DDI-PubMed.25913040.s47.e2" e2="DDI-PubMed.25913040.s47.e2" /><pair ddi="false" e1="DDI-PubMed.25913040.s47.e2" e2="DDI-PubMed.25913040.s47.e1" /></sentence><sentence text="" /></document>